JAZZ

The Insiders Fund Not So Daily Podcast | Insider Buy Sell Ratio

Insider Buying Week 05-16-25 The Best Insider Buy/Sell Ratio in a Year

by

  The busiest week we’ve seen in some time.  In fact, it’s so busy that I would venture to say that a short-term bottom is in and there is a more room to the upside.  It’s basically all in now and I don’t often make a call like that. Of course, we won’t know that for months, but this is the most bullish Insider Buy/Sell Ratio in a year.  At least it gives us a lot to ponder. There are a lot of compelling insider buys this week.  As usual insiders are value buyers, preferring to buy their stocks nearer … Read more

Insider Buying Week 03-08-24 FOMO or FEAR?

by

I’ve been struggling to explain the speculative frenzy I sense in the markets. Stocks routinely go up and down 20% on earnings or even something as trivial as an analyst upgrade or downgrade yet the underlying market seems calm, benign even. The VIX, which is the current mathematic model for measuring short-term volatility, steadily trends lower. The VIX is a measure of the volatility of the S&P 500, and by now, everyone understands that the capitalization-weighted nature of that index dominates the recent stock market performance. The popular but obsolete already term ‘Magnificent 7’ refers to a handful of mega … Read more

Quiet Insider Buying Shortened Week May 29th 2020

by

Jazz Pharmaceutical Director Seamus Mulligan bought 50,000 shares at $111.08. Before investors pile in behind that enforcement, it’s worth considering Mulligan bought 50,000 shares back in 11/15/18 at $144.56. JAZZ had a few analyst downgrades after releasing last quarter’s earnings report. JAZZ is a leader in sleep medicine and has a growing hematology/oncology portfolio. Dynavax Technologies DVAX is a startup biotech.  The priced a 14M share offering at $5 below the last closing price osf $5.66. Director Jack bought 1,000,000 shares at $5. Do you think he knew that DVAX would announce a week letter that Sky would report a … Read more